Safety and Efficacy of Second-Generation Everolimus-Eluting Xience V Stents Versus Zotarolimus-Eluting Resolute Stents in Real-World Practice Patient-Related and Stent-Related Outcomes From the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries

  • Park, Kyung Woo; 
  • Lee, Joo Myung; 
  • Kang, Si-Hyuck; 
  • Ahn, Hyo-Suk; 
  • Yang, Han-Mo; 
  • ... Gwon, Hyeon-Cheol; 
  • 외 11명
Citations

WEB OF SCIENCE

44
Citations

SCOPUS

47

초록

Objectives This study sought to compare the safety and efficacy of the Xience V/Promus everolimus-eluting stent (EES) (Abbott Vascular, Temecula, California) with the Endeavor Resolute zotarolimus-eluting stent (ZES-R) (Medtronic Cardiovascular, Santa Rosa, California) in "all-comer" cohorts. Background Only 2 randomized controlled trials have compared these stents. Methods The EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) and RESOLUTE-Korea registries prospectively enrolled 3,056 patients treated with the EES and 1,998 patients treated with the ZES-R, respectively, without exclusions. Stent-related composite outcomes (target lesion failure [TLF]) and patient-related composite outcomes were compared in crude and propensity score-matched analyses. Results Of 5,054 patients, 3,830 (75.8%) had off-label indication (2,217 treated with EES and 1,613 treated with ZES-R). The stent-related outcome (82 [2.7%] vs. 58 [2.9%], p = 0.662) and the patient-related outcome (225 [7.4%] vs. 153 [7.7%], p = 0.702) did not differ between EES and ZES-R, respectively, at 1 year, which was corroborated by similar results from the propensity score-matched cohort. The rate of definite or probable stent thrombosis (18 [0.6%] vs. 7 [0.4%], p = 0.306) also was similar. In multivariate analysis, off-label indication was the strongest predictor of TLF (adjusted hazard ratio: 2.882; 95% confidence interval: 1.226 to 6.779; p = 0.015). Conclusions In this robust real-world registry with unrestricted use of EES and ZES-R, both stents showed comparable safety and efficacy at 1-year follow-up. Overall incidences of TLF and definite stent thrombosis were low, even in the patients with off-label indication, suggesting excellent safety and efficacy of both types of second-generation drug-eluting stents. (J Am Coll Cardiol 2013; 61: 536-44) (C) 2013 by the American College of Cardiology Foundation

키워드

clinical outcome; everolimus-eluting stent; patient-oriented composite outcome; Resolute zotarolimus-eluting stent; stent thrombosis; target lesion failure; PERCUTANEOUS CORONARY INTERVENTION; ARTERY-DISEASE; RANDOMIZED-TRIALS; COMERS TRIAL; END-POINTS; REVASCULARIZATION; METAANALYSIS; IMPACT
제목
Safety and Efficacy of Second-Generation Everolimus-Eluting Xience V Stents Versus Zotarolimus-Eluting Resolute Stents in Real-World Practice Patient-Related and Stent-Related Outcomes From the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries
저자
Park, Kyung Woo; Lee, Joo Myung; Kang, Si-Hyuck; Ahn, Hyo-Suk; Yang, Han-Mo; Lee, Hae-Young; Kang, Hyun-Jae; Koo, Bon-Kwon; Cho, Janghyun; Gwon, Hyeon-Cheol; Lee, Sung Yoon; Chae, In-Ho; Youn, Tae-Jin; Chae, Jei Keon; Han, Kyoo-Rok; Yu, Cheol Woong; Kim, Hyo-Soo
DOI
10.1016/j.jacc.2012.11.015
발행일
2013-02-05
유형
Article
저널명
Journal of the American College of Cardiology
권
61
호
5
페이지
536 ~ 544